Cost-effectiveness of thrombolysis vs. standard care for stroke in a public hospital in Bogotá.
Objective: Evaluate the cost-effectiveness of intravenous thrombolysis in the treatment of the ischemic stroke compared to standard medical management, in a public hospital in Bogotá, during the period from January to December 2024. Methods: Observational, cross-sectional study with retrospective da...
| Published in: | Revista Mexicana de Neurociencia Vol. 27; no. 3; pp. 129 - 140 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Published: |
Academia Mexicana de Neurologia
May/Jun2026
|
| Subjects: | |
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=194249339&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 194249339 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 16655044 R1Q jtl: Revista Mexicana de Neurociencia issn: 16655044 maglogo: N pubinfo: dt: May/Jun2026 vid: 27 iid: 3 pid: 20851 pub: Academia Mexicana de Neurologia artinfo: ui: 194249339 10.24875/RMN.25000042 ppf: 129 ppct: 11 formats: fmt: @attributes: type: P size: 587KB tig: atl: Cost-effectiveness of thrombolysis vs. standard care for stroke in a public hospital in Bogotá. aug: au: Estrada-Matos, Jhonatan Betancourt-Ayala, Andrés M. Tocora-Rodríguez, Juan C. Moreno-Vargas, Eder A. Jiménez-Ortiz, Daniela Sobrino-Mejía, Fidel affil: Department of Neurophysiology, Bellvitge University Hospital, Barcelona, Spain Neurovascular Group, USS Kennedy, Bogotá, Colombia Andean Area University Foundation, Faculty of Health and Sports Sciences, Master's Program in Epidemiology, Bogotá, Colombia Neurology Specialization Program, Universidad de la Sabana, Bogotá, Colombia Neurology Department, USS Kennedy, Bogotá, Colombia su: Cost effectiveness Thrombolytic therapy Public hospitals Therapeutics Ischemic stroke Quality-adjusted life years Colombia Bogotá (Colombia) sug: subj: Colombia Bogotá (Colombia) Cost effectiveness Thrombolytic therapy Public hospitals Therapeutics Ischemic stroke Quality-adjusted life years keyword: Cost-effectiveness analysis Reperfusion Stroke Thrombolysis Accidente cerebrovascular Análisis de costo-efectividad Reperfusión Trombólisis ab: Objective: Evaluate the cost-effectiveness of intravenous thrombolysis in the treatment of the ischemic stroke compared to standard medical management, in a public hospital in Bogotá, during the period from January to December 2024. Methods: Observational, cross-sectional study with retrospective data collection, using a sample of patients with ischemic stroke who received intravenous thrombolysis and those who did not, at Kennedy Hospital in Bogotá, Colombia. An economic evaluation was conducted to estimate the incremental cost-effectiveness ratio (ICER) of intravenous thrombolysis compared to standard medical management. Results: The number of patients who received thrombolysis was 82, while 156 patients received standard medical management. The average cost was $13,316,428.31 (3.269,77 USD) (SD $9,147,043/2.246 USD) for the thrombolysis group and $12,813,094 (3.146,17 USD) (SD $12,261,577/3.010 USD) for the non-thrombolysis group. The thrombolysis group showed a gain of 0.27 quality-adjusted life years (QALYs) with a higher cost of $503,334 (123,59 USD) compared to the standard medical management group, resulting in an ICER of $1,864,201 (457,74 USD) per QALY. The mean utility of 5.9 (SD 4.7) [95% confidence interval [CI]: 1.52-10.27; p = 0.16] for the thrombolyzed group, while for the non-thrombolyzed group, the mean was 5.35 (SD 4.6) [95% CI: 1.03-9.68; p = 0.23], the mean delta utility was 0.54 (SD 0.28) [95% CI: 0.28-0.80; p = 0.02] and the mean ICER per QALY was -1,473,833 (SD 1,656,379) [95% CI: -3,212,096 to 264,430; p = 0.81]. Conclusions: Thrombolytic therapy is associated with greater cost-effectiveness, better clinical outcomes, and reduced disability compared to standard medical management without thrombolytic therapy. Objetivo: Evaluar la costoefectividad de la trombólisis en el tratamiento del ACV isquémico, en comparación con el manejo médico estándar, en un hospital público de Bogotá, durante el período de enero a diciembre de 2024. Métodos: Estudio observacional, transversal, con recolección retrospectiva de datos, utilizando una muestra de pacientes con ACV isquémico que recibieron trombólisis endovenosa y aquellos que no la recibieron, en el Hospital de Kennedy en Bogotá, Colombia. Resultados: El número de pacientes que recibieron trombolisis fue de 82, mientras que 156 pacientes recibieron manejo médico estándar. El costo promedio fue de $13,316,428.31 (3.269,77 USD) (SD $9,147,043/2.246 USD) para el grupo con trombólisis y de $12,813,094 (3.146,17 USD) (SD $12,261,577/3.010 USD) para el grupo sin trombólisis. El grupo con trombólisis mostró una ganancia de 0.27 AVAC (QALYs) con un costo adicional de $503,334 (123,59 USD) en comparación con el grupo de manejo médico estándar, resultando en una RCEI de $1,864,201 (457,74 USD) por AVAC. La utilidad media fue de 5.9 (DE 4.7) [IC 95%: 1.52-10.27; p = 0.16] para el grupo trombolizados, mientras que para el grupo no trombolizados fue de 5.35 (DE 4.6) [IC 95%: 1.03-9.68; p = 0.23]; la diferencia media de utilidad (delta) fue de 0.54 (DE 0.28) [IC 95%: 0.28-0.80; p = 0.02] y la RCEI media por AVAC fue de -1,473,833 (DE 1,656,379) [IC 95%: -3,212,096 a 264,430; p = 0.81]. Conclusiones: La terapia trombolítica se asocia con una mayor costoefectividad, mejores resultados clínicos y menor discapacidad en comparación con el manejo médico estándar sin trombólisis. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: Revista Mexicana de Neurociencia holder: Academia Mexicana de Neurologia dt: @attributes: year: 2026 holdings: @attributes: islocal: N |
|---|